Fusion Pharmaceuticals shares are trading higher after Raymond James upgraded the stock from Outperform to Strong Buy and raised its price target from $12 to $15.
Portfolio Pulse from Benzinga Newsdesk
Fusion Pharmaceuticals' stock (FUSN) has been upgraded by Raymond James from Outperform to Strong Buy, with an increased price target from $12 to $15, leading to higher trading of the shares.
December 27, 2023 | 1:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Raymond James upgraded Fusion Pharmaceuticals to Strong Buy from Outperform and raised the price target to $15 from $12, positively impacting the stock.
Analyst upgrades typically lead to positive short-term price movement as they suggest a stronger confidence in the company's future performance. The increase in price target further bolsters this outlook, likely leading to increased investor interest and a rise in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100